低危MDS患者每日或每周三次皮下给予极低剂量地西他滨的.docx

ASH ASH DACOGEN Time Section Board # Abs No. / Title / Authors Friday，Dec 4th, Satellite NA Dr. Jean Pierre Eisai Symposia – “Emerging Strategies for the Trea 2009 Meeting challenges” Sunday, December 6, Oral 2009: 5:30 PM Session Conference Auditorium AB (Ernest N. Morial NA 119 A Phase II Randomized Bayesian Study of Very Low Dose Subcutaneous Decitabine Ad Lower Risk Myelodysplastic Syndrome (MDS) 低危 MDS 患者每日或每周三次皮下给予极低剂量地西他滨的II 期随机研究 Convention Center) Guillermo Garcia-Manero, MD1, Daniel R. Couriel, MD2, Francesco Paolo Tambaro, MD, PhD Kadia, MD5, Elias Jabbour, MD1, Gautam Borthakur, MD1, Stefan Faderl, MD1, Willie Newso Karen Stein, MD6* and Hagop Kantarjian, MD1 Monday, December 7, Oral NA 591 Genome-Wide Analysis of DNA Methylation Patterns Reveals Dynamic Epigenetic Regul 2009: 3:15 PM Session DNA 甲基化模式的全基因组分析揭示地西他滨治疗后AML 基因组的动态表观遗传学调节作用。 R06-R09 (Ernest N. Morial Convention Center) Fabienne Brenet, Ph.D.1*, Michelle Moh, MS1*, Patricia Funk, BS1*, Daoqui You, MS2*, Agn Joseph M. Scandura, MD, PhD4 Saturday, December 5, Poster Poster Board I- 1769 Efficacy and Safety of Romiplostim in Patients with Low or Intermediate-Risk Myelodysp 2009, 5:30 PM-7:30 PM Hall E (Ernest N. Morial Convention Center) 791 低危及中危MDS 患者使用地西他滨治疗MDS 同时使用血小板生成药物Romiplostim 的疗效和 Saturday, December 5, 2009, 5:30 PM-7:30 PM Hall E (Ernest N. Morial Convention Center) Poster Poster Board I-75 [1053 Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leu Outcome in Previously Untreated Patients 地西他滨联合吉姆单抗奥佐米星治疗初治的AML 和高危MDS 的 2 期研究 Gautam Borthakur, Guillermo Garcia-Manero, MD*, Zeev Estrov, MD*, Marina Konopleva, MD MD, Tapan Kadia, MD, Betsy Williams, RN*, Solly George* and Hagop Kantarjian, MD* Sunday, December 6, Poster Poster Board II- [2089 Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diag 2009, 6:00 PM-8:00 PM Hall E (Ernest N. Morial Convention Center) Sunday, December 6, 2009, 6:00 PM-8:00 PM Hall E (Er